Merck details skin disease drug data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 30 September, 2026

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

news Lilly's triple-G allows more than half of patients to drop below obesity line Merck shows off mid-stage win for Prometheus drug in painful skin disease Zealand and Roche's amylin works best at middle dose, trails Lilly's

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS PHARMA PhRMA picks Eric Cantor as next chief Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech Exclusive: SK pharmteco unveils $200M+ investment to expand CDMO capabilities Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic disease BioNTech to close three sites in Germany after failing to secure a sale

in case you missed it 1. Updated: UniQure sinks as Huntington's gene therapy appears to show waning benefit over time